What uric acid is and where 6.8 comes from
Uric acid is the end product of purine metabolism, made in the body and taken in through food, and cleared mainly by the kidneys. The number 6.8 mg/dL is not a statistical percentile like most reference limits. It is approximately the point at which urate saturates plasma, above which monosodium urate crystals can form in joints and tissues. That is why the ACR anchors its definition of hyperuricemia there rather than at a lab's upper reference limit.
Crystal formation is what causes gout, so the physical chemistry gives the threshold a real meaning. What it does not give is a prediction. Plenty of people sit above the saturation point for decades and never form a crystal that causes trouble.
The recommendation people do not expect
The ACR guideline generated 42 recommendations, 16 of them strong. Buried among the conditional ones is the answer to the question most people arrive with. In the guideline's own words: for patients with asymptomatic hyperuricemia, meaning serum urate above 6.8 mg/dL with no prior gout flares or subcutaneous tophi, the panel conditionally recommends against initiating any pharmacologic urate-lowering therapy. The certainty of evidence attached to it is rated high.
That combination is worth pausing on. A conditional recommendation usually signals weak or absent evidence. Here it is conditional despite high certainty evidence, which means the panel was confident about the size of the effect and still judged it too small to be worth treating for most people. The reasoning is set out with the numbers.
Randomized trials designed to study cardiovascular outcomes did show a significant reduction in incident gout flares over three years. But incident gout was uncommon in both arms, under 1 percent with treatment against 5 percent without, which produces that number needed to treat of 24 over three years. Observational data pointed the same way: among people with asymptomatic hyperuricemia above 9 mg/dL, only about 20 percent developed gout within five years.
The panel extended the recommendation to people with comorbid chronic kidney disease, cardiovascular disease, kidney stones or high blood pressure, judging that the benefits still would not outweigh the costs and risks for the large number unlikely to progress. It also covers people whose imaging shows urate crystal deposition without any flare or tophus.
Once you have had gout, everything changes
The evidence for treating gout is much stronger than the evidence for treating a number, and the recommendations reflect it. Among the strong recommendations, the panel supports starting urate-lowering therapy for anyone with tophaceous gout, radiographic joint damage from gout, or frequent flares, defined as two or more per year.
| Situation | ACR 2020 recommendation | Strength |
|---|---|---|
| Tophi, radiographic damage, or 2 or more flares per year | Start urate-lowering therapy | Strong |
| More than one previous flare but fewer than 2 per year | Start urate-lowering therapy | Conditional |
| First flare, otherwise uncomplicated | Do not start urate-lowering therapy | Conditional |
| First flare with CKD stage 3 or worse, urate above 9 mg/dL, or kidney stones | Start urate-lowering therapy | Conditional |
| Urate 6.8 mg/dL or above, no flares, no tophi | Do not start urate-lowering therapy | Conditional, high certainty evidence |
Sponsored option
Vetted Aug 19, 2026Affiliate link, we may earn a commission at no extra cost to you.
Everlywell Our score 4.0/5
At-home lab tests
Pricing as of Aug 19, 2026
HbA1c $49; cholesterol and lipids $49; heart health panel $99
The target, and how treatment is meant to be run
When treatment is indicated, the ACR is specific about how. A treat-to-target strategy, with the dose titrated against repeat serum urate measurements to a target below 6 mg/dL, is a strong recommendation. So is allopurinol as the preferred first-line agent for all patients, explicitly including those with moderate to severe chronic kidney disease.
Two further strong recommendations shape the first months and explain experiences that otherwise seem like treatment failure. Start low: allopurinol at 100 mg per day or less, lower in kidney disease, or febuxostat below 40 mg per day. And take anti-inflammatory prophylaxis alongside for at least three to six months, because lowering urate mobilises existing crystal deposits and can trigger flares early in treatment. A flare in the first weeks of allopurinol is expected, not evidence the drug is wrong.
For the flare itself, colchicine, non-steroidal anti-inflammatory drugs, or glucocorticoids given orally, into the joint, or by injection are all strongly recommended, which leaves useful room to work around kidney disease, ulcers, anticoagulation and diabetes.
What this means for a number on a report
If you have never had a gout attack and your uric acid came back at 7.4, the guideline's position is that this is not, on its own, something to medicate. That does not make it uninformative. High urate travels with the metabolic cluster of raised blood pressure, insulin resistance, central weight gain and kidney impairment, and those things are worth attention on their own evidence rather than through urate. Our guide to the metabolic numbers to know after 40 covers that panel, and the eGFR guide covers the kidney side.
The ACR guideline is also careful about its own limits: it does not directly address the impact of gout or hyperuricemia on cardiovascular disease, hypertension, kidney stones or chronic kidney disease. Someone claiming the guideline proves lowering urate does or does not protect the heart is reading something into it that is not there.
Our uric acid reference page carries the treatment target with its source and effective date, and the lab result lookup will place a specific value against it.
Frequently asked questions
What is a normal uric acid level?
Laboratories print their own reference intervals, which differ between labs and between men and women. The clinically meaningful number in the gout literature is 6.8 mg/dL, roughly the saturation point above which urate crystals can form, and below 6 mg/dL, the treatment target once someone has gout.
My uric acid is high but I have never had gout. Should I take allopurinol?
The ACR conditionally recommends against starting urate-lowering therapy in that situation, on high certainty evidence, and extends that to people who also have kidney disease, cardiovascular disease, kidney stones or high blood pressure. Conditional means the decision can reasonably go the other way after a discussion, but the default is no.
Will changing my diet fix a high uric acid?
Diet moves urate less than most people expect, generally by a fraction of the amount a modest dose of a urate-lowering drug achieves. That is not an argument for ignoring alcohol, sugary drinks and very high purine intake, particularly during a flare, but it is a reason not to expect diet alone to bring a substantially raised level under the treatment target.
Why did my gout get worse after starting allopurinol?
This is expected early on, which is why the ACR strongly recommends anti-inflammatory prophylaxis for at least three to six months alongside starting treatment. Lowering blood urate mobilises deposits already in the joints, and that can provoke flares before things settle.
Can uric acid be measured during a flare?
It can, but the value can be misleading, because urate often falls during an acute attack and a normal level in that moment does not exclude gout. If the number is being used to guide long-term treatment, a measurement taken away from a flare is more informative.
When to talk with a clinician
Seek care for an acutely hot, swollen, exquisitely painful joint, particularly with fever, because a joint infection can look very like gout and is an emergency. For a raised uric acid with no symptoms, the conversation is not urgent, and the two useful questions are whether the number changes anything given no history of flares, and what else on the panel, kidney function and blood pressure especially, deserves attention in its own right.
